|
|
 |
|
|
Functional Properties of Edible Mushrooms by
Dr. Raymond
Chang, M.D., F.A.C.P.
Commonly known mushrooms that are both edible and have functional
properties include Auricularia (mu-er),Flammulina (enokitake),
Grifola (rnaitake), Hericium, Lentinus (shiitake), Pleurotus
(oyster), and Tremella (yiner). Most edible mushrooms, however, do
not have medicinal value (e.g., Agaricus bisporus), and some
medicinal mushrooms (e.g. Ganoderma, Coriolus) are not edible. Of
the
10,000
known species of mushrooms, it is currently thought that
700
are edible and >200 may have medicinal value, although only a small
percentage of these mushrooms are available to the consumer.1
Although many cultures have used mushrooms as both food and
medicine, the use of mushrooms as a functional food is most notable
in the East, where application of mushrooms to maintain health was
formally recorded as early as 100 AD in China. Mushrooms have been
incorporated into health tonics, tinctures, teas, soups, arid
healthful food dishes, as well as herbal formulas. Within the
framework of traditional medicine, mushrooms have been applied to
lubricate the lungs (Tremella fuciformis), tonify the kidneys (Cordyceps
sinensis), reduce excessive dampness (Grifola umbellate), and
invigorate the spleen (Poria cocos). More recently, functional
mushrooms have been shown to modulate the immune system, lower blood
pressure and blood lipid concentrations, and inhibit tumors,
inflammation, and microbial action. I will discuss the shiitake (Lentinus
edodes) as a model of the functional mushrooms with demonstrated
bioactivity because it is widely consumed as a food in the East and
increasingly in the West, arid extensive research on its bioactivity
has led to the isolation of pure compounds that have reached
pharmaceutical status.
Shiitake as a Model for Functional Mushrooms
Shiitake is the common Japanese name for Lentinus edodes, and is
also the common name now used in the West. Indigenous to Asia,
shiitake is now cultivated and is the second most commonly produced
edible mushroom in the world .2 Besides being a culinary delicacy, there is a long tradition of
use of shiitake as medicine in Asia, dating back >2000 years.
Shiitake contains protein (26% of dry weight) ,
3 lipids (primarily linoleic
acid); carbohydrate; fiber; minerals; vitamins B-1, B-2, and C; and
ergosterol , 4 the D provitamin. Besides its nutritive content
several important compounds have been isolated from shiitake that
have immunomodulatory, lipid-lowering, and antimicrobial properties.
These include lentinan, Lentinus edodes mycelium (LEM), KS-2, and
eritadenine. Of these, lentinan is the most studied.
In 1969, Ikekawa et al .5 noted that a water extract of shiitake fruiting bodies could inhibit
transplanted tumors in mice. Around the same time, Chihara et al .6
isolated an antitumor polysaccharide from shiitake and named it
lentinan. The molecular formula for lentinan is (C6H10O5)n,
and the mean molecular mass is 500 kDa. Lentinan is a D-glucan as
shown by electrophoresis, ultracentrifugation, and other
instrumental analyses, Its structure was confirmed as ( 1,
3)-D-glucopyranan with a branched chain of (1,6)-monoglycosyl,
showing a right-handed triple helix.
7
,8
Lentinan has been found to activate macrophages, Tlymphocytes, and
other immune effector cells that modulate the release of cytokines,
which may in turn account for its indirect antitumor and
antimicrobial properties .9
The antitumor effects of lentinan are believed to be a result of
immunopotentiation, which has been demonstrated in allogeneic,
syngeneic, and autologous rodent tumor test systems and confirmed in
randomized, controlled clinical trials in humans.10
For example, Taguchi
11 reported significant
improvement(p<0.01) in survival in patients with advanced gastric
cancer who were treated with lentinan and chemotherapy compared with
those treated with chemotherapy alone. The antimicrobial effects of
lentinan are also believed to be enacted via immunologic
potentiation of host defenses, which has been demonstrated against
bacterial, viral, and parasitic infections.12
Other biologically active polysaccharide fractions have also been
conjugate as its major active constituent.
13 It is active orally, and has been studied mostly
for its antiviral properties, In a clinical trial of 4O patients
with chronic hepatitis B, LEM improved liver function and reduced
viremia, 14 More interestingly, LEM has been shown to inhibit
human immunodeficiency virus (HIV) infection in vitro
15 and may hove promise as a
therapy for acquired immunodeficiency syndrome. Another compound
isolated from shiitake is eritadenine, which has been shown to lower
serum cholesterol and lipid concentrations in various studies in
rodents.
16,17
Besides the well-studied compounds just discussed, other potentially
beneficial compounds have been found in shiitake. One example is
thioproline, which blocks the formation of carcinogenic N-nitroso
compounds.18
A purified compound is very different from the whole
mushroom, however, and the inevitable questions that follow are
whether eating the whole mushroom has preventive or therapeutic
value, and if so, how much mushroom should be consumed and in what
form. For shiitake, researchers found that the powdered mushroom
fruit bodies given to rats as 10-20% of their diet inhibited
transplanted tumors,
19,20
and small studies have demonstrated lipid-lowering effects
consumption of 9 g of dried mushrooms or 90 g of fresh mushrooms.21
The content and potency of bioactive ingredients may differ
depending on how the mushroom is prepared and ingested. For example,
the anticarcinogenic thioproline content varies from undetectable
amounts in fresh shiitake, to 134 mg/100 g of dried shiitake, to 843
mg/100 g of boiled shiitake.18
As is the case for most plants and herbs, the specific strain,
growing conditions, and other environmental factors will also
significantly affect the taste, form, and substance of the mushroom,
as well as affect the bioactive content.22
Summary
Edible mushrooms such as shiitake may have important salutary
effects on health or even in treating disease. A mushroom
characteristically contains many different bioactive compounds with
diverse biological activity, and the content and bioactivity of
these compounds depend on how the mushroom is prepared and consumed.
It is estimated that
5O%
of the annual 5 million metric tons of cultivated edible mushrooms
contain functional "nutraceutical" or medicinal properties.2 In
order of decreasing cultivated tonnage, Lentinus (shiitake),
Pleurotus (oyster),Auricularia (mu-er), Flammulina (enokitake),
Tremella (yin-er) Hericium, and Grifola (maitake) mushrooms have
various degrees of immunomodulatory, lipid-lowering, antitumor, and
other beneficial or therapeutic health effects without any
significant toxicity.
Although the data for this functional food class are not as strong
as those for other functional foods such as cruciferous vegetables,
because of their potential usefulness in preventing or treating
serious health conditions such as cancer, acquired immune deficiency
syndrome (AIDS), and hypercholesterolemia. Functional mushrooms
deserve further serious investigation. Additionally, there is a need
for epidemiological evidence of the role of this functional food
class.
|
1.
|
Kendriok B. The Fifth
Kingdom. Waterloo: Mycologue Publication, 1985 |
|
2.
|
Chang ST. Mushroom biology: the impact on mushroom production
and mushroom products. In: Chang ST. Buswell JA. Chiu SW, eds.
Mushroom Biology and Mushroom Products. Hong Kong: Chinese
University Press. 1993:3-20
|
|
3.
|
Terashita T, Kono M, Mishima N, Obata T, Yamauchi M. The
proximate components, free and protein-bound amino acids in
protein and 5'GMP in fruit-bodies of Lentinus edodesSinger
Shiitake mushroom grown on artificial bed-blocks. J Jpn Soc
Food Sci Technol 1990; 37 :528-32
|
|
4. |
Ying J, Mao X, Ma Q, Zong Y,". Wen H. Icons of medicinal fungi
from China. Beijing: Science Press, 1987
|
|
5. |
Ikekawa T, Uehara N, Maeda Y. Nankinishi M, Fukuoka F.
Antitumor activity of aqueous extracts of edible mushrooms.
Cancer Res 1969;29:734-5-5
|
|
6. |
Chihara G, Hamuro J, Maeda Y, Arai Y, Fukuoka F. Fractionation
and purification of the polysaccharides with marked antitumor
activity especially Lentinan, from Lentinus edodes (Berk.).
Sing., an edible mushroom. Cancer Res 1970;30:2776-81
|
|
7. |
Sasaki T, and Takasuka N ,Further study of the structure of
lentinan, an antiturnor polysaccharide from Lentinus edodes.
Carbohydr Res 1976;47:99-104
|
|
8. |
Bluhm TL, Sarco A. The triple helical structure of lentinan,
aß-(1 -3)-D-glucan Can J Chem 1977; 55:293-9-9
|
|
9. |
Hamuro J, Chihara G. Lentinan, a T-cell oriented
immunopotentiator: its experimental and clinical applications
and possible mechanism of immune modulation. In: Fenichel RL,
Chirigos MA, eds. Immune Modulation Agents and Their
Mechanisms. New York: Marcel Dekker, 1985:409-36
|
|
10. |
Chihara G, Hamuro J, Maeda Y, et al. Antitumor and metastasis
inhibitory activities of lentinan as an immunomodulator.
Cancer Detect Prev 1 987;(Suppl 1 ):423-43
|
|
11. |
Taguchi T. Clinical efficacy of lentinan on patients with
stomach cancer: end-point results of a four-year follow-up
survey. Cancer Detect Prev 1987;(suppl 1):333-49
|
|
12. |
Kaneko Y, Chihara G. Potentiation of host resistance against
microbial infections by lentinan and its related
polysaccharides. In: Friedman H, ed. Microbial Infections. New
York: Plenum. 1992:201-15
|
|
13. |
Sugano N, Hibino Y, Choji Y, Maeda H. Anticarcinogenic actions
of water-soluble and alcohol-insoluble fractions from culture
medium of Lentinus edodes mycelia. Cancer lett 1982:17:109-14
|
|
14. |
Amagasse H. Treatment of heaptitis B patients with Lentinus
edodes mycelia. In: New Trends in Peptic Ulcer and Chronic
Hepatitis. Part II. Chronic Hepatitis. Princeton: Exerpta
Medica 1987;316-21
|
|
15. |
Tochikura T. Nakashima H, Ohashi Y, Yamamoto N. Inhibition (in
vitro) of replication and of the cytopathic effect of human
immunodeficiency virus by an extract of the culture medium of
Lentinus edodes mycelia. Med Microbiol Immunol 1988;177:235-44
|
|
16. |
Yamamura Y, Cochran KW. Chronic hypocholesterolemic effect of
Lentinus edodes in mice and absence of effect on scrapie.
Science 1974;9:489-93
|
|
17. |
Chibata I, Okumura K, Takeyama S. Kotera K. Lentinacin: a new
hypochoLesterolemic substance in Lentinus edodes. Specialia
Experentia 1969;25:1237-8
|
|
18. |
Kurashirna Y, Tsuda M, Sugimura T. Marked formation of
thiazolidine-4-carboxylic acid, an effective nitrite trapping
agent in vivo, on boiling of dried shiitake mushroom (Lentinus
edodes). J Agric Food Chem 1990;38:1945-9-9
|
|
19. |
Nanba H. Antitumor action of Shiitake (Lentinus edodes) fruit
bodies orally administered to mice Chem Pharm Bull
1967;35:2459-6-6
|
|
20. |
Mori K, Toyomasu T, Nanba H, Kuroda H. Antitumor activities of
edible mushrooms by oral administration. In: Wuest PJ, Royse
DJ, Beelman RB, eds. Proceedings of the International
Symposium on Scientific and Technical Aspects of Cultivating
Edible Fungi. Amsterdam: Elsevier, 1987:1-6
|
|
21. |
Susuki S, Oshirna S. Influence of Shi-Ta-Ke(lentinus edodes)
on human serum cholesterol. Mushroom Sci 1 976;9 (Part 1):
463-7
|
|
22. |
Royse DJ, Bahler CC. Effects of genotype, spawn run time and
substrate formulation on biological efficiency of shitake.
Appl Environ Microbial I996;52:1425-7
|
|
|
|